Trial: 202101091

A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations

Phase

II (Cancer Control)

Principal Investigator

Thaker, Premal

Disease Site

Anus; Bones and Joints; Brain and Nervous System; Breast; Cervix; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Ill-Defined Sites; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Melanoma, Skin; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid; Unknown Sites; Urinary Bladder

Learn more about this study at: clinicaltrials.gov